Vaccine-Derived Poliovirus: Challenges and Solutions

Introduction

Polio is a crippling and potentially fatal infectious disease that has been on the research agenda to eradicate for many years. Due to vigorous efforts in immunization, the incidence of WPV has reduced drastically all over the world. However, as WPV recedes, another form of the virus has emerged as a significant challenge: The type of poliovirus that may emerge from such post-vaccination acute flaccid paralysis (AFP) cases and has been also acknowledged globally is the vaccine-derived poliovirus (VDPV). VDPVs result from the emergence of a new strain of poliovirus in the oral polio vaccine that is weakened but has become neurovirulent again. This is a new phenomenon to public health officials, as the tool given to eliminate polio can under certain circumstances provoke an outbreak. This article provides an analysis of VDPVs, the causes of their occurrence, and the complex measures that are being taken to deal with them.

Understanding Vaccine-Derived Poliovirus (VDPV)

VDPVs develop from the oral polio vaccine, which has a live but weakened virus that for a long time has been administered orally. OPV is prepared from a weakened strain of the poliovirus; during vaccination, the virus multiplies in his intestines for a few days as it gives immunity to the child. At this stage, the virus also comes out in feces, causing a spread in areas with poor hygiene standards. In low immunization coverage communities, the excreted vaccine virus will go around the community, infecting the susceptible population. This virus, surprisingly, can mutate its genes within many cycles of infection to become a form that paralyzes people just like the wild poliovirus. These reverted strains are a type of circulating vaccine-derived poliovirus (cVDPV).

Factors Contributing to VDPV Emergence

Several factors contribute to the emergence and spread of VDPVs:

Several factors contribute to the emergence and spread of VDPVs: Several factors contribute to the emergence and spread of VDPVs:

Low Immunization Coverage: The major attributable risk factors include the following: Low coverage of immunization. Low vaccination levels permit the circulation of the vaccine virus for a longer period, and therefore, the chances of reversion to the original form are improved.

Sanitation and Hygiene: Their next administration is oral, and the flu inevitably spreads via the fecal-oral route due to poor sanitation and hygiene.

Mutation and Recombination: The process whereby new genes are developed in the vaccine virus is due to mutations as they continue to transfer from one individual to the other. Collectively, these changes may lead to the emergence of a virus that is fully capable of provoking an illness.

Immunocompromised Individuals: Immunocompromised patients are capable of shedding the virus for a long time due to the prolonged replication of the virus, thus increasing the rates of mutations.

Yearwise Publication Trend on poliovirus

Find publication trends on relevant topics

Global Distribution and Impact

The effects of VDPVs have been devastating, particularly in areas of conflict, political instability, and heuristic health facilities. For instance, the latest news covers peaceful outbreaks in some Asian countries like Afghanistan, Pakistan, and some African countries. However, these regions fail to achieve high immunization coverage and also have problems with sanitation and healthcare infrastructure. The circulation of VDPVs in these areas compromises the gains of polio eradication across the world.

Strategies to Combat VDPVs

Addressing the challenges posed by VDPVs requires a multifaceted approach. Addressing the challenges posed by VDPVs requires a multifaceted approach:

Improving Immunization Coverage: Special emphasis should be placed on compliance with its full schedule in every child selected; polio would be easier to combat if it infected only one child in a thousand. The population with high rates of immunization is protected. from both WPV and VDPV. This comprises seasonal immunization, SIA, and special targeted campaigns in high-risk zones.

Switching to Inactivated Polio Vaccine (IPV): The Global Polio Eradication Initiative (GPEI) has advised the shift from OPV to the inactivated polio vaccine (IPV); the vaccine contains a bit of ‘dead’ virus that cannot foster the disease. This switch also minimizes the probability of the emergence of VDPV. Currently, numerous countries have included IPV in the immunization programs.

Enhanced Surveillance: VDPV spreads are easier to track compared to other poliomyelitis varieties; however, it is crucial to identify and mitigate them as soon as possible. This entails enhancing AFP surveillance to look for any AFP cases and environmental surveillance in looking for poliovirus in sewage. These concepts can prevent the spread of disease, and if an outbreak occurs, rapid response teams can be used to stop the spread of the disease.

Development of Novel OPV: Researchers are also accustomed to using the oral polio vaccine; a newer version, nOPV2, has been created and is genetically more stable compared to OPV. This vaccine is designed to lessen the possibility of reverting to a virile strain while passing the advantages of oral immunization.

Strengthening Health Systems: Strengthening resilient health systems is a key component of both polio eradication as well as overall health system strengthening. This entails raising awareness among healthcare practitioners, enhancing the facilities, and having reliable, steady, and adequate sources of vaccines.

Recent Publications on poliovirus

Find publications on relevant topics

Case Studies and Regional Responses

Afghanistan and Pakistan: These countries are the only ones still considered endemic for the wild poliovirus type and have experienced at least VDPV1 epidemics. Measures that are taken to reduce polio in these areas include the provision of immunization to children, a process that entails difficulties because of political turmoil and strife in many African countries. For such endeavors to bear fruit, it is crucial to have the support of local health authorities, backed up by the international community.

Africa: Some of the African countries have reported outbreaks of cVDPV. In response, there have been collaborative approaches to upturn immunization and the incorporation of nOPV2 in outbreak response strategies. There have also been enhancements of surveillance in the African region that enable early identification of poliovirus and quick response.

Challenges in Implementation

Of course, some difficulties appear when the mentioned strategies are being practiced. High levels of immunization, however, in hard-to-reach places such as remote areas and conflict-prone areas require going through various challenges as far as access is concerned as well as trust. Another challenge is vaccine hesitancy, which is found in people’s reluctance to adhere to vaccination programs out of perceived fear or adherence to cultural norms. Moreover, due to financial and resource limitations, many of the lower-income countries are likely to experience a dilemma in procuring new vaccines and technologies.

The Future of Polio Eradication

The polio fight is at a tipping point. Even though the global transmission of wild poliovirus is on the verge of being interrupted, the occurrence of VDPVs is another complex situation. Maintenance of such commitment, advancement of development of subsequent generations of vaccines, as well as further reinforcement of health systems, are believed to be major to tackling these challenges. The issues that have been highlighted in the fight against polio will also be very useful in the fight against other infectious diseases, hence enhancing world health.

Conclusion

VDPVs demonstrate the factors involved in the process of elimination of a disease uniquely focused on at the worldwide level. Hence, the researchers point out that the measures should be more encompassing and dynamic, which focus not only on the biomedical aspect of the virus but also on the social, economic, and physical structures. Vaccination, changing over to safer vaccines, and efforts in improving the methods of surveillance and analysis for polio have brought into focus VDPVs, about which the world community can substantially reduce the risks for the close arrival of a polio-free world.

References

  1. Stehling-Ariza T, Wilkinson AL, Diop OM, Jorba J, Asghar H, Avagnan T, Grabovac V, Johnson T, Joshi S, Kfutwah AKW, Sangal L, Sharif S, Wahdan A, Tallis GF, Kovacs SD. Surveillance To Track Progress Toward Poliomyelitis Eradication – Worldwide, 2021-2022. MMWR Morb Mortal Wkly Rep. 2023 Jun 9;72(23):613-620. doi: 10.15585/mmwr.mm7223a1. PMID: 37289657; PMCID: PMC10328463.
  2. Sadigh, K.S., 2022. Progress toward poliomyelitis eradication―Afghanistan, january 2020–november 2021. MMWR. Morbidity and Mortality Weekly Report71.
  3. Alleman, M.M., 2021. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2020–June 2021. MMWR. Morbidity and mortality weekly report70.
  4. Bigouette, J.P., 2021. Progress toward polio eradication—worldwide, January 2019–June 2021. MMWR. Morbidity and mortality weekly report70.
  5. Chard, A.N., 2020. Progress toward polio eradication—worldwide, January 2018–March 2020. MMWR. Morbidity and mortality weekly report69.
  6. Thompson, K.M., Kalkowska, D.A. and Badizadegan, K., 2022. Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative. Gates Open Research6.
  7. Kalkowska, D.A., Pallansch, M.A., Cochi, S.L. and Thompson, K.M., 2021. Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response vaccine options. The Journal of Infectious Diseases224(9), pp.1529-1538.
  8. Thompson, K.M. and Kalkowska, D.A., 2021. An updated economic analysis of the Global Polio Eradication Initiative. Risk Analysis41(2), pp.393-406.

Top Experts on “poliovirus